Huiqing Zhang | Cancer | Best Researcher Award

Posted on by Pencis

Mr. Huiqing Zhang | Cancer | Best Researcher Award

Jiangxi Cancer Hospital | China

Author Profile

Scopus

📌 HUIQING ZHANG – A LEADING FIGURE IN DIGESTIVE ONCOLOGY

🏛 EARLY ACADEMIC PURSUITS

Huiqing Zhang embarked on his medical journey with a strong foundation in oncology, specializing in digestive oncology. His rigorous academic training provided him with extensive knowledge of gastrointestinal malignancies, diagnostic methodologies, and therapeutic advancements. His pursuit of excellence led him to gain specialized expertise in oncology, which would later define his career trajectory.

💼 PROFESSIONAL ENDEAVORS

Dr. Zhang has held key positions in prominent cancer institutions in China, demonstrating a steady and impactful career progression:

  • December 2018 – Present: Chief Physician, Department of Digestive Oncology, Jiangxi Cancer Hospital.
  • December 2015 – December 2018: Deputy Chief Physician, Department of Digestive Oncology, Jiangxi Cancer Hospital.
  • March 2017 – March 2018: Vice President (on secondment) and Deputy Chief Physician at Ganzhou Cancer Hospital.
  • December 2015 – November 2016: Visiting Scientist at MD Anderson Cancer Center, Gastroenterology.
  • November 2010 – December 2015: Attending Physician, Department of Digestive Oncology, Jiangxi Cancer Hospital.
  • August 2008 – November 2010: Physician, Oncology Department, Jiangxi Cancer Hospital.

Throughout his career, Dr. Zhang has played a pivotal role in advancing digestive oncology treatments, contributing significantly to the hospital’s clinical and research excellence.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER

Dr. Zhang’s research primarily focuses on gastrointestinal cancer therapies, tumor microenvironments, and precision medicine approaches. His work has contributed to the development of innovative treatment modalities, improving patient outcomes in digestive oncology. His tenure at MD Anderson Cancer Center exposed him to cutting-edge research methodologies, which he has integrated into his clinical practice in China.

🌍 IMPACT AND INFLUENCE

As a Chief Physician, Dr. Zhang has been instrumental in pioneering advanced treatment strategies for digestive cancer patients. His leadership at Jiangxi Cancer Hospital has strengthened its reputation as a leading institution for cancer care in China. Additionally, his role as Vice President at Ganzhou Cancer Hospital further expanded his influence in shaping policies and implementing progressive medical protocols.

📚 ACADEMIC CITATIONS

Dr. Zhang’s research contributions have been widely cited in scientific journals, reflecting his influence in the field of digestive oncology. His studies on novel therapeutic strategies and advancements in endoscopic cancer treatments are frequently referenced by oncologists and researchers worldwide.

🏆 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Zhang’s legacy is defined by his unwavering commitment to oncology research and patient care. His future contributions are expected to focus on expanding precision medicine applications, enhancing immunotherapy approaches, and fostering international collaborations to improve gastrointestinal cancer treatment. As a seasoned researcher and physician, he continues to inspire upcoming oncologists and remains a key figure in advancing cancer therapy in China and beyond.

📑NOTABLE PUBLICATIONS 

"Mutation on JmjC domain of UTX impaired its antitumor effects in pancreatic cancer via inhibiting G0S2 expression and activating the Toll-like signaling pathway" 

  • Authors: X., Shen, Xiaohua , S., Xiong, Shuping , S., Wang, Shengpeng , Y., Wan, Yiye , H., Zhang, Huiqing
  • Journal: Molecular Medicine
  • Year: 2024

Sang Yeon Cho | Molecular Cancer Biology | Best Researcher Award

Posted on by Pencis

Dr. Sang Yeon Cho | Molecular Cancer Biology | Best Researcher Award

Chungna National University | South Korea

Author Profile 

Scopus

Google Scholar

BIOGRAPHY OF SANG YEON CHO 🌟

EARLY ACADEMIC PURSUITS 🎓

Sang Yeon Cho embarked on his academic journey at Chungnam National University, where he earned his Bachelor's degree in Biochemistry in 2012. He further pursued an M.S. in Medicine, obtaining his MD degree in 2021. Currently, he is completing his Ph.D. in New Drug Discovery and Development, expected to graduate in February 2025. His strong foundation in the sciences has equipped him with the skills necessary for innovative research in the medical field.

PROFESSIONAL ENDEAVORS 🏥

Currently, Dr. Cho serves as the Vice Director of the Metro Neurosurgery Clinic in Daejeon, South Korea, since October 2022. Prior to this role, he was the Vice Director of Hurisarang Hospital from March 2021 to September 2022. His leadership positions reflect his commitment to advancing medical practice and enhancing patient care.

CONTRIBUTIONS AND RESEARCH FOCUS ON MOLECULAR CANCER BIOLOGY 🔬

As the Director of ChoLab since 2018, Dr. Cho has focused on cancer genomics and new drug discovery. His research has investigated the molecular mechanisms underlying cancer, emphasizing drug resistance and therapeutic targets. He has actively contributed to several labs, including the Neuroglia Lab and the Nano Primo Research Center, showcasing his multidisciplinary approach to tackling complex medical challenges.

IMPACT AND INFLUENCE 🌍

Dr. Cho's work has significantly influenced the field of medical genetics and cancer research. His publications in high-impact journals highlight the clinical significance of his findings, making substantial contributions to understanding cancer prognosis and treatment. Through his research, he aims to bridge the gap between laboratory discoveries and clinical applications, improving patient outcomes.

ACADEMIC CITATIONS 📚

His research output includes numerous peer-reviewed articles in respected journals such as BMC Medical Genomics, Scientific Reports, and BMC Cancer, where he explores topics like drug resistance, immunotherapy biomarkers, and cancer prognosis. His findings have garnered attention and citations within the academic community, underscoring the relevance and quality of his work.

LEGACY 🏆

Dr. Cho's dedication to advancing cancer research and patient care has already left a mark on the field. His innovative approach, exemplified by multiple patents related to AI in healthcare and cancer diagnostics, positions him as a forward-thinking researcher poised to shape future developments in medical science.

FUTURE CONTRIBUTIONS 🔮

Looking ahead, Dr. Cho aims to continue his research in cancer treatment and drug discovery, integrating cutting-edge technologies like artificial intelligence to enhance therapeutic strategies. With his expected Ph.D. completion in 2025, he is set to further expand his contributions to the field and inspire the next generation of medical researchers.

NOTABLE PUBLICATIONS 📑

"A method for the observation of the primo vascular system in the thoracic duct of a rat" 

  • Authors: Kim, S., Jung, S.J., Cho, S.Y., Soh, K.-S., Kim, S.
  • Journal: Evidence-based Complementary and Alternative Medicine
  • Year: 2013

"Protocol for the Observation of the Primo Vascular System in the Lymph Vessels of Rabbits" 

  • Authors: Jung, S.J., Cho, S.Y., Bae, K.-H., ... Song, Y.-K., Soh, K.-S.
  • Journal:  Journal of Acupuncture and Meridian Studies
  • Year: 2012

Hongmeng Su | Gene Regulations | Best Researcer Award

Posted on by Pencis

Dr. Hongmeng Su | Gene Regulations and Epigenetics |  Best Researcer Award

Southeast University | China

Author Profile

Scopus

EARLY ACADEMIC PURSUITS

Hongmeng Su embarked on an academic journey marked by a strong foundation in bioengineering, which laid the groundwork for subsequent achievements. Graduating with a Bachelor of Engineering in Bioengineering from Nanjing Agriculture University in 2019, Su's early academic pursuits showcased a dedication to biological sciences and a burgeoning interest in research.

PROFESSIONAL ENDEAVORS

Transitioning seamlessly from undergraduate to graduate studies, Su pursued a Master of Science in Biology at the School of Life Science and Technology, Southeast University, from 2019 to 2021. This period not only honed Su's research skills but also provided a platform for academic growth and exploration in the field of biology.

CONTRIBUTIONS AND RESEARCH FOCUS ON GENE REGULATIONS AND EPIGENETICS

Su's contributions to the field of medical genetics and developmental biology are underscored by a multifaceted approach to understanding the molecular mechanisms driving hepatocellular carcinogenesis. Through meticulous research endeavors, Su has delved into the intricate interplay between non-coding RNA, transcription factors, and carcinogenesis, shedding light on key pathways implicated in cancer progression and metastasis.

IMPACT AND INFLUENCE

Su's research findings have garnered recognition and accolades, affirming the significance of their contributions to the scientific community. Notably, Su's report on the combined analysis of m6A and m5C RNA methylation modulators received honorable mention at the 10th Member Congress and Academic Seminar of Jiangsu Genetic Association, showcasing the impact of their work on hepatocellular carcinoma prognosis.

ACADEMIC CITATIONS

Su's scholarly endeavors have contributed to the advancement of knowledge in medical genetics, developmental biology, and cancer research. Their publications serve as a testament to their dedication to scientific inquiry and the dissemination of impactful findings within the academic community.

LEGACY AND FUTURE CONTRIBUTIONS

As a Ph.D. candidate at the Department of Medical Genetics & Developmental Biology, School of Medicine, Southeast University, Su's legacy is characterized by a commitment to unraveling the complexities of hepatocellular carcinogenesis. Armed with a diverse skill set encompassing molecular and cellular experimentation, bioinformatics analysis, and statistical modeling, Su is poised to make enduring contributions to the field of cancer biology and beyond. Their future endeavors hold the promise of further elucidating the molecular underpinnings of cancer progression, informing novel therapeutic strategies, and ultimately, advancing human health.

Notable Publications

TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p 2021(35)

ETV4 facilitates angiogenesis in hepatocellular carcinoma by upregulating MMP14 expression

Prognostic value of PD-L1 expression combined with hypoxia-associated immunosuppression in hepatocellular carcinoma